Drug Trial Radar · NCT06110676
A Study to Evaluate the Efficacy and Safety of LZM012
Last checked: Nov 19, 2026Latest source record: Nov 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
918
Planned (sponsor's estimate)
Start
Aug 21, 2023
Primary completion
Apr 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
Conditions
- Psoriasis
Interventions
LZM012Biological
Recombinant anti-human IL-17A/F humanized monoclonal antibody injection
SecukinumabBiological
Cosentyx
Primary outcomes
What the sponsor says the trial is designed to measure.
- PASI100 response rateTime frame: At week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.